A detailed history of Israel Englander (Millennium Management LLC) transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 494,226 shares of KZR stock, worth $3.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
494,226
Previous 628,514 21.37%
Holding current value
$3.15 Million
Previous $377,000 0.8%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.53 - $0.77 $71,172 - $103,401
-134,288 Reduced 21.37%
494,226 $380,000
Q2 2024

Aug 14, 2024

SELL
$0.6 - $0.92 $113,075 - $173,382
-188,459 Reduced 23.07%
628,514 $377,000
Q1 2024

May 15, 2024

SELL
$0.8 - $1.05 $1.69 Million - $2.22 Million
-2,110,590 Reduced 72.09%
816,973 $735,000
Q4 2023

Feb 14, 2024

SELL
$0.72 - $1.15 $585,753 - $935,577
-813,546 Reduced 21.75%
2,927,563 $2.78 Million
Q2 2023

Aug 14, 2023

BUY
$2.31 - $3.06 $2.78 Million - $3.68 Million
1,204,006 Added 47.46%
3,741,109 $9.17 Million
Q1 2023

May 15, 2023

SELL
$3.13 - $7.31 $1.12 Million - $2.63 Million
-359,392 Reduced 12.41%
2,537,103 $7.94 Million
Q4 2022

Feb 14, 2023

SELL
$6.39 - $8.8 $420,289 - $578,802
-65,773 Reduced 2.22%
2,896,495 $20.4 Million
Q3 2022

Nov 14, 2022

BUY
$7.99 - $10.75 $1.7 Million - $2.29 Million
213,322 Added 7.76%
2,962,268 $25.5 Million
Q2 2022

Aug 15, 2022

BUY
$4.58 - $17.13 $8.37 Million - $31.3 Million
1,826,884 Added 198.13%
2,748,946 $22.7 Million
Q1 2022

May 16, 2022

BUY
$12.3 - $18.33 $6.54 Million - $9.74 Million
531,420 Added 136.04%
922,062 $15.3 Million
Q4 2021

Feb 14, 2022

BUY
$7.44 - $16.72 $2.81 Million - $6.31 Million
377,366 Added 2842.47%
390,642 $6.53 Million
Q3 2021

Nov 15, 2021

SELL
$4.85 - $9.73 $3.82 Million - $7.67 Million
-788,085 Reduced 98.34%
13,276 $115,000
Q2 2021

Aug 16, 2021

BUY
$4.93 - $6.46 $103,919 - $136,170
21,079 Added 2.7%
801,361 $4.35 Million
Q1 2021

May 17, 2021

SELL
$5.24 - $6.99 $764,379 - $1.02 Million
-145,874 Reduced 15.75%
780,282 $4.65 Million
Q4 2020

Feb 16, 2021

BUY
$4.77 - $6.58 $1.31 Million - $1.81 Million
275,027 Added 42.24%
926,156 $4.84 Million
Q3 2020

Nov 16, 2020

SELL
$4.36 - $5.5 $905,776 - $1.14 Million
-207,747 Reduced 24.19%
651,129 $3.15 Million
Q2 2020

Aug 14, 2020

BUY
$3.6 - $7.75 $2.62 Million - $5.64 Million
727,187 Added 552.2%
858,876 $4.45 Million
Q1 2020

May 14, 2020

BUY
$2.77 - $5.75 $301,035 - $624,892
108,677 Added 472.26%
131,689 $574,000
Q4 2019

Feb 14, 2020

BUY
$2.5 - $4.26 $19,890 - $33,892
7,956 Added 52.84%
23,012 $92,000
Q3 2019

Nov 14, 2019

SELL
$3.0 - $7.58 $141,483 - $357,480
-47,161 Reduced 75.8%
15,056 $49,000
Q2 2019

Aug 15, 2019

SELL
$7.09 - $21.9 $1.12 Million - $3.45 Million
-157,418 Reduced 71.67%
62,217 $480,000
Q2 2019

Aug 14, 2019

BUY
$7.09 - $21.9 $1.56 Million - $4.81 Million
219,635 New
219,635 $39.9 Million
Q4 2018

Feb 14, 2019

SELL
$20.21 - $32.9 $1.1 Million - $1.8 Million
-54,628 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$15.5 - $21.41 $318,060 - $439,333
-20,520 Reduced 27.31%
54,628 $1.17 Million
Q2 2018

Aug 14, 2018

BUY
$17.15 - $17.79 $1.29 Million - $1.34 Million
75,148 New
75,148 $1.3 Million

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $436M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.